Heron Therapeutics Inc(NASDAQ:HRTX) Soars 60% After positive results from Phase 3 MAGIC Study of SUSTOL Print E-mail
By David Fowler   
Friday, 29 May 2015 21:12

Heron Therapeutics Inc. (NASDAQ:HRTX) has confirmed robust top-line results from the recently completed Phase 3 MAGIC study.


MAGIC had assessed the efficiency as well as safety of firm’s 5-HT3receptor antagonist product candidate SUSTOL and was a part of three-drug regimen with intravenous neurokinin-1 receptor antagonist fosaprepitant and the IV corticosteroid dexamethasone for preventing delayed-onset chemotherapy-induced nausea and vomiting after administration of highly emetogenic chemotherapy agents.


The study is exclusive Phase 3 CINV prophylaxis study in HEC population done because of use as a comparator and was conducted completely in U.S. with enrolment of over 900 patients going through HEC treatment for numerous tumor types.


The first endpoint in the study was proportion of patients having achieved complete response with no rescue medications occurring in delayed-onset phase of CINV and happening 24-120 hours after HEC agents. The study’s major findings were that the primary endpoint was achieved. It also stated the percentage of patients achieving Complete Control reached statistical significance in favor of SUSTOL. Besides this, the study showed that the percentage of patients experiencing no nausea or infrequent nausea during delayed-onset phase was quite higher in SUSTOL arm vis-a-vis the comparator arm. More number of patients in SUSTOL arm were satisfied with therapy based on quality-of-life questionnaire.


SUSTOL was tolerated with no significant differences in severity of adverse events between the SUSTOL arm and comparator arm.


Schnadig, M.D., Principal Investigator, US Oncology Research, Compass Oncology, Tualatin, Oregon, opined that the study demonstrated that use of SUSTOL with an NK1 receptor antagonist for patients getting HEC significantly reduced symptoms of CINV.


Jeffrey Vacirca, M.D., Principal Investigator, North Shore Hematology/Oncology Associates, opined that the advantage with SUSTOL in Complete Response and overall satisfaction with therapy is impressive.


Shares of the company soared 60% to $19.76 after hitting a new high of $21.22 in Friday’s session.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!